Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

[1]  A. Bonnet,et al.  A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death , 2010, Neurobiology of Aging.

[2]  C. Warren Olanow,et al.  Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.

[3]  F. Schmitt,et al.  Lewy Body Pathology in Normal Elderly Subjects , 2009, Journal of neuropathology and experimental neurology.

[4]  A. Aguzzi.  Cell biology: Beyond the prion principle , 2009, Nature.

[5]  Z. Wszolek,et al.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.

[6]  D. Surmeier.  A Lethal Convergence of Dopamine and Calcium , 2009, Neuron.

[7]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[8]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[9]  Andrew King,et al.  Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.

[10]  Ole Isacson,et al.  Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.

[11]  M. Farrer,et al.  DCTN1 mutations in Perry syndrome , 2009, Nature Genetics.

[12]  H. Braak,et al.  Neuroanatomy and pathology of sporadic Parkinson's disease. , 2008, Advances in anatomy, embryology, and cell biology.

[13]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[14]  I. Ferrer,et al.  Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience , 2008, Dementia and Geriatric Cognitive Disorders.

[15]  T. Iwatsubo,et al.  Lewy Body Pathology Involves Cutaneous Nerves , 2008, Journal of neuropathology and experimental neurology.

[16]  D. Dickson,et al.  Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.

[17]  P. Mcgeer,et al.  The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease , 2008, Experimental Neurology.

[18]  C. Adler,et al.  Evaluation of α-synuclein immunohistochemical methods used by invited experts , 2008, Acta Neuropathologica.

[19]  D. Dickson,et al.  Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[20]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[21]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[22]  I. McKeith,et al.  Patterns and stages of α-synucleinopathy , 2008, Neurology.

[23]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  Satoshi Orimo,et al.  Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .

[25]  O. Hornykiewicz,et al.  Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an Eyewitness , 2008, Neurodegenerative Diseases.

[26]  Susan M. Resnick,et al.  Morphometry of the human substantia nigra in ageing and Parkinson’s disease , 2008, Acta Neuropathologica.

[27]  I. Alafuzoff,et al.  Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance , 2008, Acta Neuropathologica.

[28]  K. Jellinger,et al.  Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease , 2008, Acta Neuropathologica.

[29]  I. Ferrer,et al.  Assessment of &agr;-Synuclein Pathology: A Study of the BrainNet Europe Consortium , 2008, Journal of neuropathology and experimental neurology.

[30]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of α-synuclein , 2008, Experimental Neurology.

[31]  G. Halliday,et al.  The progression of pathology in longitudinally followed patients with Parkinson’s disease , 2008, Acta Neuropathologica.

[32]  T. Montine,et al.  RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient , 2008, Brain pathology.

[33]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of alpha-synuclein. , 2008, Experimental neurology.

[34]  A. Kakita,et al.  Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. , 2008, Brain : a journal of neurology.

[35]  J. Trojanowski,et al.  Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations , 2008, Acta Neuropathologica.

[36]  C. Adler,et al.  Reduced striatal tyrosine hydroxylase in incidental Lewy body disease , 2008, Acta Neuropathologica.

[37]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[38]  John L. Robinson,et al.  Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases , 2007, Acta Neuropathologica.

[39]  T. Iwatsubo,et al.  Analysis of the Adrenal Gland Is Useful for Evaluating Pathology of the Peripheral Autonomic Nervous System in Lewy Body Disease , 2007, Journal of neuropathology and experimental neurology.

[40]  D. Dickson,et al.  Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. , 2007, Parkinsonism & related disorders.

[41]  Vladimir N Uversky,et al.  Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. , 2007, Journal of neurochemistry.

[42]  T. Gasser.  Update on the genetics of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[43]  E. Perry,et al.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.

[44]  K. Jellinger.  The morphological basis of mental dysfunction in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[45]  Dennis W. Dickson,et al.  Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy , 2006, Journal of neuropathology and experimental neurology.

[46]  K. Jellinger,et al.  Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? , 2006, Acta Neuropathologica.

[47]  A. Probst,et al.  α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects , 2006, Neuropathology and applied neurobiology.

[48]  M. Graeber,et al.  Comparative study of commercially available anti‐α‐synuclein antibodies , 2006, Neuropathology and applied neurobiology.

[49]  A. Bonnet,et al.  Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. , 2006, Archives of neurology.

[50]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[51]  G. Schellenberg,et al.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. , 2006, Archives of neurology.

[52]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[53]  I. Alafuzoff,et al.  Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject , 2005 .

[54]  Kay L. Double,et al.  α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease , 2005 .

[55]  W. Noble,et al.  Molecular motors implicated in the axonal transport of tau and α-synuclein , 2005, Journal of Cell Science.

[56]  R. Hilker,et al.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.

[57]  J. Trojanowski,et al.  Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire , 2005, Neuron.

[58]  Y. Mizuno,et al.  Relationship between Parkinson disease with dementia and dementia with Lewy bodies. , 2005, Parkinsonism & related disorders.

[59]  D. Dickson,et al.  Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? , 2005, Parkinsonism & related disorders.

[60]  I. Alafuzoff,et al.  α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia , 2005, Annals of neurology.

[61]  I. Alafuzoff,et al.  Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[62]  W. Noble,et al.  Molecular motors implicated in the axonal transport of tau and alpha-synuclein. , 2005, Journal of cell science.

[63]  K. Double,et al.  Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. , 2005, Brain : a journal of neurology.

[64]  Bin Zhang,et al.  Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.

[65]  C. Tanner,et al.  Parkinsonian signs and substantia nigra neuron density in decendents elders without PD , 2004, Annals of neurology.

[66]  Dag Aarsland,et al.  Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity? , 2004, Journal of geriatric psychiatry and neurology.

[67]  A. Davies,et al.  Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons , 2004, Journal of Cell Science.

[68]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[69]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[71]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[72]  D. Dickson,et al.  Colocalization of Tau and Alpha‐Synuclein Epitopes in Lewy Bodies , 2003, Journal of neuropathology and experimental neurology.

[73]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[74]  Hideo Fujiwara,et al.  Accumulation of phosphorylated alpha-synuclein in aging human brain. , 2003, Journal of neuropathology and experimental neurology.

[75]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[76]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[77]  J. Trojanowski,et al.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.

[78]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[79]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[80]  N. Hattori,et al.  Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification , 2000, Brain and Development.

[81]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[82]  M. Spillantini.  Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. , 1999, Parkinsonism & related disorders.

[83]  H. Shinotoh.  [Dementia with Lewy bodies and Parkinson's disease with dementia]. , 1999, Rinsho shinkeigaku = Clinical neurology.

[84]  A. Rajput.  Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. , 1999, Neurology.

[85]  H. Braak,et al.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.

[86]  K. Iwanaga,et al.  Lewy body–type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases , 1999, Neurology.

[87]  M. Spillantini.  Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. , 1999, Parkinsonism & related disorders.

[88]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[89]  S. Murayama,et al.  Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.

[90]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[91]  P. Blumbergs,et al.  Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.

[92]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[93]  James Lowe,et al.  Establishing a Pathological Diagnosis in Degenerative Dementias , 1998, Brain pathology.

[94]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[95]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[96]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[97]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[98]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[99]  M. Uchiyama,et al.  Incidental Lewy body disease in a patient with REM sleep behavior disorder , 1995, Neurology.

[100]  A. Lees,et al.  Parkinson's Disease Society Brain Bank, London: overview and research. , 1993, Journal of neural transmission. Supplementum.

[101]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[102]  M. Yoshimura,et al.  Lewy body disease with and without dementia: a clinicopathological study of 35 cases. , 1988, Clinical neuropathology.

[103]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[104]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[105]  C. Saper,et al.  Preservation of hypothalamic dopaminergic neurons in Parkinson's disease , 1985, Annals of neurology.